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Introduction {#jdi12235-sec-0001}
============

Type 2 diabetes is increasing in prevalence worldwide[1](#jdi12235-bib-0001 jdi12235-bib-0002){ref-type="ref"}, and it is strongly associated with obesity and insulin resistance[3](#jdi12235-bib-0003 jdi12235-bib-0004){ref-type="ref"}, as well as defects in pancreatic β‐cell function and mass[5](#jdi12235-bib-0005 jdi12235-bib-0006){ref-type="ref"}. These metabolic disorders impede the critical regulatory influence of insulin on glucose, lipid and protein metabolism, thus precipitating a disease characterized by impairments in these physiological processes. However, it takes years to develop frank diabetes. Patients developing type 2 diabetes have often gone through a state of obesity associated with reduced insulin sensitivity along with an activated β‐cell compensatory mechanism, such as excess basal insulin secretion and hyperproinsulinemia, as a part of their metabolic profile[7](#jdi12235-bib-0007){ref-type="ref"}. These pathological conditions occur early in the disease progression of type 2 diabetes[8](#jdi12235-bib-0008){ref-type="ref"}, and before the β‐cells severely fail in late stage (insulin‐dependent) type 2 diabetes[8](#jdi12235-bib-0008 jdi12235-bib-0009){ref-type="ref"}.

To combat type 2 diabetes, there is an urgent need for more effective treatments and therapeutic regimens. Thoroughly characterized and clinically relevant type 2 diabetes animal models are required to achieve this aim of testing new and better therapeutics. Both genetic spontaneous diabetes models and experimentally‐induced non‐spontaneous diabetes models exist. An example of an experimentally‐induced animal model of diabetes is the high‐fat diet/streptozotocin treated (HFD/STZ) rat model. This model involves a combination of a diet high in fat, and in some cases sugar, to bring about hyperinsulinemia, insulin resistance and/or glucose intolerance followed by treatment with the β‐cell toxin STZ, which results in a severe reduction in functional β‐cell mass[10](#jdi12235-bib-0010 jdi12235-bib-0011){ref-type="ref"}. Together, these two stressors are designed to mimic the pathology of type 2 diabetes, though on a shorter timescale than found in the human condition.

The aim of the present review is to clarify and discuss critical caveats and unanswered questions regarding the HFD/STZ rat model, which have not been discussed in the literature. First, the impact of and differences between the diet regimens in relation to obesity and type 2 diabetes will be discussed. Second, the effect of the various STZ treatments, as well as the importance of age, with respect to type 1 and type 2 diabetes, will be focused on. Finally, whether the HFD/STZ rat model mimics the early or late stages of type 2 diabetes are discussed. This disease stage classification is based on comparison of circulating metabolic measures provided in studies using the HF/STZ rat model. Classification of type 2 diabetes is an important consideration when choosing the best therapeutic intervention in patients.

In order to discuss these topics at the end of the present review, the human metabolic profile of the different stages in the disease progression of type 2 diabetes will be summarized first. Next, the history of the development of the HFD/STZ rat model will be recounted. It is beyond the scope of this review to present an overview of all existing diabetes rodent models, as many of the other models have been reviewed recently[12](#jdi12235-bib-0012 jdi12235-bib-0013 jdi12235-bib-0014 jdi12235-bib-0015){ref-type="ref"}. To summarize, the aim of the present review is to provide a guide of the factors to take into account when modeling and working with the HFD/STZ rat model.

Metabolic Profile of Healthy and Prediabetes Humans {#jdi12235-sec-0002}
===================================================

Before discussing the HFD/STZ rat model, it is important to review the stages and transitions in the progression of type 2 diabetes, which the HFD and STZ treatments are meant to emulate. The first transition is the shift from a healthy state to a prediabetes state. In prediabetes, patients have either impaired fasting glucose, impaired glucose tolerance, or both, and is often associated with insulin resistance. In healthy individuals, the adipose tissue functions as a safe storage site for lipids during a positive caloric balance[16](#jdi12235-bib-0016){ref-type="ref"}. Likewise, excess circulating glucose is accommodated by the liver and muscle tissue in the form of glycogen. In the context of fully occupied glycogen stores, high glucose levels might also bring about *de novo* lipogenesis, occurring mainly in the liver and, to a lesser extent, in the adipose tissue[17](#jdi12235-bib-0017 jdi12235-bib-0018 jdi12235-bib-0019){ref-type="ref"}. *De novo* lipogenesis helps maintain normal blood glucose levels by sequestering away excess glucose from the circulation. Normoglycemia in healthy individuals is maintained by the unique interplay between the almost opposing hormones, insulin and glucagon. The dialogue between these two hormones becomes perturbed with the disease progression of type 2 diabetes[20](#jdi12235-bib-0020 jdi12235-bib-0021 jdi12235-bib-0022){ref-type="ref"}. The transition from a metabolically healthy state to prediabetes often includes an obese state characterized by hyperinsulinemia, insulin resistance, and dyslipidemia[8](#jdi12235-bib-0008 jdi12235-bib-0023 jdi12235-bib-0024){ref-type="ref"}. However, it should be stressed that both metabolically healthy obese individuals, as well as metabolically unhealthy lean individuals, can be found in the general population[25](#jdi12235-bib-0025){ref-type="ref"}. This implies that obesity might not automatically or immediately result in the development of type 2 diabetes, and highlights that type 2 diabetes is a highly polygenic and heterogenous disease[25](#jdi12235-bib-0025 jdi12235-bib-0027){ref-type="ref"}. The nutritional overload, which in the long term leads to obesity, can quickly induce insulin resistance in skeletal muscle as well as in the liver (Figure [1](#jdi12235-fig-0001){ref-type="fig"})[28](#jdi12235-bib-0028){ref-type="ref"}. Insulin resistance in skeletal muscle might reduce the occurrence of lipotoxic effects in muscle by redirecting the excess energy to the adipose tissue stores[23](#jdi12235-bib-0023 jdi12235-bib-0029){ref-type="ref"}, and can thus be seen as a normal physiological function in healthy individuals.

![Simplified overview of the interactions between multiple tissues in type 2 diabetes. When energy input exceeds output, both blood glucose (BG) and blood triglycerides (TG) will increase, which eventually lead to ectopic fat accumulation in muscle and the liver. The consequence is insulin resistance, thus directing lipids to the adipose tissue. When the adipocytes become dysfunctional, extra ectopic fat accumulation including fat accumulation in the β‐cells occurs. Whether insulin resistance brings about hyperinsulinemia or vice versa is a highly debated topic. An increase in BG and insulin resistance both lead to induction of β‐cell compensatory mechanisms including β‐cell hypertrophy and increased insulin secretion, further contributing to hyperinsulinemia. This is a vicious cycle of first physiological events, then pathological events, and finally β‐cell death leading to a severe BG increase and full‐blown diabetes.](jdi-5-349-g1){#jdi12235-fig-0001}

Severe expansion of the adipose tissue is tightly associated with adipose inflammation and a distorted adipokine profile, marked by high leptin and low adiponectin levels[30](#jdi12235-bib-0030){ref-type="ref"} representing dysfunctional adipocytes. Dysfunctional adipose tissue leads to ectopic fat accumulation in non‐adipose tissue, such as muscle, liver, and β‐cells (Figure [1](#jdi12235-fig-0001){ref-type="fig"})[31](#jdi12235-bib-0031 jdi12235-bib-0032){ref-type="ref"}. Intramyocellular lipid accumulation is associated with insulin resistance[33](#jdi12235-bib-0033 jdi12235-bib-0034){ref-type="ref"}. Insulin‐resistant muscles have lower glycogen synthesis and redirect glucose to the liver, where it contributes to hepatic lipid accumulation through *de novo* lipogenesis (Figure [1](#jdi12235-fig-0001){ref-type="fig"})[35](#jdi12235-bib-0035){ref-type="ref"}. Hepatic fat accumulation can induce hepatic insulin resistance (Figure [1](#jdi12235-fig-0001){ref-type="fig"})[36](#jdi12235-bib-0036 jdi12235-bib-0037){ref-type="ref"}, with decreased glycogen synthesis and increased gluconeogenesis[36](#jdi12235-bib-0036){ref-type="ref"}. This impaired insulin‐induced suppression of hepatic glucose output may contribute to hyperglycemia (Figure [1](#jdi12235-fig-0001){ref-type="fig"}). Further inflammation of the abdominal adipose tissue may worsen the dysfunctional state of the adipocytes[30](#jdi12235-bib-0030 jdi12235-bib-0038){ref-type="ref"}, leading to more ectopic fat accumulation, insulin resistance and hyperinsulinemia, in a negative feedback loop (Figure [1](#jdi12235-fig-0001){ref-type="fig"}). However, beneficial aspects of inflammation, such as proliferation of certain classes of macrophages in the adipose tissue, has been illustrated[39](#jdi12235-bib-0039){ref-type="ref"}.

In the early state of type 2 diabetes progression, β‐cell compensatory mechanisms have typically adapted to preserve normoglycemia[8](#jdi12235-bib-0008 jdi12235-bib-0009){ref-type="ref"}. The compensatory mechanisms might include increased β‐cell mass, augmented β‐cell function, or a combination of both (Figure [1](#jdi12235-fig-0001){ref-type="fig"})[6](#jdi12235-bib-0006 jdi12235-bib-0008 jdi12235-bib-0009){ref-type="ref"}. β‐Cell function in this metabolic state seems to be improved through elevated insulin biosynthesis, altered glucose and lipid metabolism, as well as through enhanced incretin sensitivity and parasympathetic nervous system activity ensuing normoglycemia and hyperinsulinemia[9](#jdi12235-bib-0009){ref-type="ref"}. Despite the tight association between obesity and hyperinsulinemia and/or insulin resistance, the exact causal relationship between these phenomena is still being elucidated. Some investigators have proposed that elevated circulating insulin levels found very early in the disease progression might play a causal role in obesity and/or insulin resistance in at least some individuals[40](#jdi12235-bib-0040 jdi12235-bib-0041 jdi12235-bib-0042){ref-type="ref"}. To summarize, a simplified version of the transition from a metabolically healthy state to an obese and prediabetic state involves a vicious cycle comprising hyperinsulinemia, insulin resistance, dyslipidemia, inflamed and dysfunctional adipose tissue, ectopic fat deposition in liver and muscle, and failure of β‐cells (see Figure [1](#jdi12235-fig-0001){ref-type="fig"}).

Metabolic Profile of Human Type 2 Diabetes {#jdi12235-sec-0003}
==========================================

Genetic susceptibility increases the odds that an individual will progress from prediabetes to frank diabetes[26](#jdi12235-bib-0026 jdi12235-bib-0044){ref-type="ref"}, which is frequently defined as fasting blood glucose above 7 mmol/L (126 mg/dL)[43](#jdi12235-bib-0043){ref-type="ref"}. Interestingly, the majority of the genes discovered in genome‐wide association studies are thought to play a primary role in the pancreatic β‐cells, while having only minor roles in so‐called 'classical' insulin target tissues[26](#jdi12235-bib-0026 jdi12235-bib-0044){ref-type="ref"}. In clinical studies, β‐cell failure typically manifests as a loss of first phase insulin secretion, loss of pulsatile insulin oscillations[45](#jdi12235-bib-0045){ref-type="ref"} and an increased circulating pro‐insulin‐to‐insulin ratio[46](#jdi12235-bib-0046){ref-type="ref"}. As in the case of prediabetes, type 2 diabetes is also intimately related to dyslipidemia[33](#jdi12235-bib-0033){ref-type="ref"} and hepatic steatosis[47](#jdi12235-bib-0047){ref-type="ref"}, as well as with hypoadiponectinemia[48](#jdi12235-bib-0048){ref-type="ref"} and increased levels of the liver damage marker alanine aminotransferase[24](#jdi12235-bib-0024){ref-type="ref"}. However, essentially, the transition from the prediabetes state to frank type 2 diabetes requires the loss of a significant portion of the functional β‐cell mass[6](#jdi12235-bib-0006 jdi12235-bib-0008 jdi12235-bib-0009 jdi12235-bib-0049){ref-type="ref"}.

Functional β‐cell mass is the product of physical β‐cell mass and β‐cell function, which includes an appropriate level of glucose‐stimulated pulsatile insulin release and the appropriate suppression of basal insulin secretion. Failure of these β‐cell functions can to some extent been explained by the twin cycle hypothesis[50](#jdi12235-bib-0050){ref-type="ref"}. The idea behind this hypothesis is that hepatic lipid accumulation leads to β‐cell lipid uptake[51](#jdi12235-bib-0051){ref-type="ref"}, worsening insulin resistance, and promoting β‐cell failure and death[9](#jdi12235-bib-0009 jdi12235-bib-0051){ref-type="ref"}. The factors and mechanisms involved in programmed β‐cell death have recently been reviewed[52](#jdi12235-bib-0052){ref-type="ref"}. Importantly, the amount of physical β‐cell mass left in an individual with type 2 diabetes seems to be dependent of the duration of the disease. Consequently, the metabolic profile in type 2 diabetes patients will depend on the duration of their disease (an early vs late stage of type 2 diabetes). The choice of therapeutics will differ between patients being in either an early or late state of type 2 diabetes. The type of therapeutic intervention, lifestyle vs pharmacological therapeutics, such as insulin therapy, will further affect the metabolic profiles.

Finally, it is important to note that the cell types involved in the pathogenesis of type 2 diabetes are not solely limited to adipocytes, myocytes, hepatocytes and β‐cells. In the 2009 Banting lecture, Dr Ralph Defronzo stressed the pivotal role of all members of the 'ominous octet' in the development of glucose intolerance, which includes the brain, kidneys, alpha cells, and the gastrointestinal tract, besides the four cell types already mentioned.[53](#jdi12235-bib-0053){ref-type="ref"}.

History of the Development of the HFD/STZ Rat Model {#jdi12235-sec-0004}
===================================================

In the beginning of the new millennium, Reed *et al*.[54](#jdi12235-bib-0054){ref-type="ref"} reported a new rat model of type 2 diabetes. This model is today known as the HFD/STZ rat, as well as by other names (e.g. high energy/STZ rat). Recently, the model is most often referred to simply as a type 2 diabetes model. The aim of the study by Reed *et al*. was to develop a rat model simulating the natural diabetes pathology progression, from prediabetes and/or insulin resistance to a state of type 2 diabetes and hypoinsulinemia, in a condensed timeline. Reed *et al*.[54](#jdi12235-bib-0054){ref-type="ref"} fed 7‐week‐old Sprague--Dawley rats a diet with 40% kcal fat for 2 weeks. The presence of insulin resistance was indicated through the observation of equal glucose clearance profiles in fat and lean rats, respectively, with an increase in glucose‐induced insulin responses in the fat‐fed rats[54](#jdi12235-bib-0054){ref-type="ref"}. Subsequently, overnight‐fasted animals were dosed (i.v.) once with STZ (50 mg/kg). A total of 3 days after STZ treatment, rats that had reached an elevated blood glucose plateau were included in the study and their response to metformin was tested[54](#jdi12235-bib-0054){ref-type="ref"}. The metformin‐induced lowering of blood glucose further established the HFD/STZ model to be a rat model of type 2 diabetes relevant to the human condition. Later, another HFD/STZ rat model was generated by using a low dose of STZ[55](#jdi12235-bib-0055){ref-type="ref"}. The HFD/STZ model was then further modified by Zhang *et al*.[56](#jdi12235-bib-0056){ref-type="ref"}, wherein the STZ‐treatment comprised multiple low doses of STZ instead of a single dose. This approach was inspired by the type 1 diabetes animal model involving multiple low doses of STZ. This approach has been reported to induce an inflammation‐mediated destruction of the β‐cells instead of the fast induction of the β‐cell death induced by a single dose of STZ[56](#jdi12235-bib-0056){ref-type="ref"}. After these three key publications, several versions of the HFD/STZ rat have appeared in the literature.

Discussion of the HFD/STZ Rat Model: Disease Modeling {#jdi12235-sec-0005}
=====================================================

Impact of the Diet Regimen in Relation to Obesity and Type 2 Diabetes {#jdi12235-sec-0006}
---------------------------------------------------------------------

In the HFD/STZ rat models, the state of obesity, insulin resistance and/or glucose intolerance in prediabetes is simulated by a period of a high‐fat or 'Western' diet. Whether the rats actually reach a state of true overweight or obesity within this time period seems to depend on the duration of the fat feeding, which tends to be either relatively long (≥ 3 months)[57](#jdi12235-bib-0057){ref-type="ref"} or relatively short (2--4 weeks; Table [1](#jdi12235-tbl-0001){ref-type="table-wrap"}). Furthermore, the classification of overweight and obesity in humans is based on body mass index and can also be defined as abnormal or excessive fat accumulation that might impair health ([www.who.int](http://www.who.int)). However, it is often unclear how one can apply this definition to rodents. Unfortunately, no standardized definition of rodent obesity exists. Hence, the actual presence of obesity in the various HFD/STZ rats should always be taken into consideration when working with this model. Besides the duration of the HFD feeding timeframe, the composition of the diet seems to greatly affect the weight gain and fat distribution[58](#jdi12235-bib-0058){ref-type="ref"}. The diets used in the HFD/STZ model vary in both nutritional composition and source of the nutrients (Table [1](#jdi12235-tbl-0001){ref-type="table-wrap"}). Some studies utilized a diet high in carbohydrates to produce a 'high energy' feeding regimen. However, the most commonly used approach is to feed rats with a diet high in fat, but with normal levels of sugar.

###### Summary of high‐fat diet‐fed, streptozotocin rat studies

  References                                                     STZ[\*](#jdi12235-note-0001){ref-type="fn"}   Diet[†](#jdi12235-note-0001){ref-type="fn"}^,^[‡](#jdi12235-note-0001){ref-type="fn"}   Initial age/BW        Strain[§](#jdi12235-note-0001){ref-type="fn"}   Metabolic measures[¶](#jdi12235-note-0001){ref-type="fn"}                                                         T2D stage ([\*\*](#jdi12235-note-0001){ref-type="fn"}^,^[††](#jdi12235-note-0001){ref-type="fn"})
  -------------------------------------------------------------- --------------------------------------------- --------------------------------------------------------------------------------------- --------------------- ----------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
  Hu *et al*.[83](#jdi12235-bib-0083){ref-type="ref"}            1 × 30--35                                    12W, 26K, 15.2P, 58F^L^, %                                                              10--12 weeks          SD                                              PG = 22 (H), PI = 191 (H), HOMA‐IR^ς^ = (H)                                                                       Early (T2D)
  Abo‐Elmatty *et al*.[78](#jdi12235-bib-0078){ref-type="ref"}   1 × 35                                        2W, 17C, 25P, 58F^L^, %                                                                 --                    A                                               FBG = 18 (H), SI = 86 (S), HbA1c = 10 (H), TG = 1.5 (H), LDL = 3.2 (H), HDL = 0.6 (L)                             Late (T2D)
  Gandhi *et al*.[79](#jdi12235-bib-0079){ref-type="ref"}        1 × 40                                        2W, 73ND, 25F^CN^, 2CO                                                                  180 ± 10 g            W                                               FBG = 17 (H), PI = 198 (H), TG = 1.7 (H), TC = 2.5 (H)                                                            Early (T2D)
  Khan *et al*.[84](#jdi12235-bib-0084){ref-type="ref"}          1 × 35                                        2W, 20C^S^, 10F^L^, 2.5CO, 1O                                                           230 ± 20 g            SD                                              FG = 14 (H), FI = 111 (L), TG = 1.4 (H), C = 5.7 (H), HDL = 0.5 (L), LDL = 1.5 (H), HOMA‐IR = (H), HOMA‐B = (L)   Late (T2D)
  Ren *et al*.[85](#jdi12235-bib-0085){ref-type="ref"}           1 × 30                                        6W, 67ND, 20C^S^, 10F^L^, 2CO, 1O                                                       8 weeks/180--220 g    SD                                              --                                                                                                                NA (T2D)
  Hou *et al*.[86](#jdi12235-bib-0086){ref-type="ref"}           1 × 25                                        20C, 20P, 59F                                                                           200--220 g            SD                                              TG = 18 (H)                                                                                                       NA (T2D)
  Guo *et al*.[60](#jdi12235-bib-0060){ref-type="ref"}           1 × 30                                        4W, 67ND, 20C^S^, 10F^L^, 1O                                                            140--180 g            W                                               ISI = (L)                                                                                                         NA (T2D)
  Mahmoud *et al*.[87](#jdi12235-bib-0087){ref-type="ref"}       1 × 35                                        2W, 41C, 18P, 40F                                                                       190 ± 10 g            RN                                              G = 16 (H), HbA1c = 9 (H), I = 108 (L), HOMA‐IR = (H)                                                             Late (T2D)
  Si *et al*.[69](#jdi12235-bib-0069){ref-type="ref"}            1 × 50 i.v.                                   2W, 41C, 18P, 40F                                                                       7 weeks, 200 g        SD                                              BG = (H)                                                                                                          NA
  Guo *et al*.[88](#jdi12235-bib-0088){ref-type="ref"}           1 × 30                                        4W, 67ND, 20C^S^, 10F^L^, 1O                                                            140--180 g            W                                               PG = 18 (H), PI = 206 (H), TG = 1.7 (H), TC = 3.5 (H), IRI = (H)                                                  Early (T2D)
  Hussein *et al*.[89](#jdi12235-bib-0089){ref-type="ref"}       1 × 35 i.v.                                   2W, 3C^S,\ ST^, 74P^SB,\ MP^, 23F^VO^, 1O                                               15--21 weeks          SD                                              FG = 13, FI = 107, TG = 2.1, TC = 5.2, HD = 1.0, LDL = 3.7, [¶¶](#jdi12235-note-0001){ref-type="fn"}              NA (T2D)
  Guo *et al*.[90](#jdi12235-bib-0090){ref-type="ref"}           1 × 30                                        4W, 67ND, 20C^S^, 10F^L^, 1O                                                            140--180 g            W                                               PG = 17 (H), PI = 299 (H), TG = 1.5 (H), TC = 2.8 (H), IRI = (L)                                                  Early (T2D)
  Sharma *et al*.[80](#jdi12235-bib-0080){ref-type="ref"}        1 × 40                                        1.5W, 73ND, 25F^CN^, 2CO                                                                170--200 g            W                                               BG = 17 (H), I = 123 (H), APQ = (H), TG = (H), HDL = (L), LDL (H), HOMA‐IR = (H), HOMA‐B = (L)                    Early (T2D)
  Albersen *et al*.[59](#jdi12235-bib-0059){ref-type="ref"}      2 × 20                                        2W, ND added 10F^L^, 2CO                                                                12 weeks              SD                                              BG\>17, SI = (L), TG = (H), TC = (H), LDL = H), HDL = (H)                                                         NA (T2D)
  Lu *et al*.[65](#jdi12235-bib-0065){ref-type="ref"}            1 × 30                                        8W, 30C, 22P, 12F, 3O                                                                   8 weeks, 250 ± 20 g   W                                               BG\>11, HbA1C = 8, TG = 1.4, C = 2.0, HDL = 1.5, LDL = 0.2, [¶¶](#jdi12235-note-0001){ref-type="fn"}              NA (T2D)
  Parveen *et al*.[91](#jdi12235-bib-0091){ref-type="ref"}       1 × 40                                        2W, 41C, 18P, 40F, %                                                                    160--200 g            W                                               HbA1c = 11, [¶¶](#jdi12235-note-0001){ref-type="fn"}                                                              NA (DS)
  Zou *et al*. 2010[92](#jdi12235-bib-0092){ref-type="ref"}      1 × 25                                        8W, 25.6C, 16.4P, 58F, %                                                                220--250 g            SD                                              FBG = 20, SI = 86, HbA1c = 7, [¶¶](#jdi12235-note-0001){ref-type="fn"}                                            NA (T2D)
  Xing *et al*.[93](#jdi12235-bib-0093){ref-type="ref"}          1 × 30                                        6W, 66ND, 20C^S^, 10F^L^, 2.5CO, 1O                                                     170--200 g            SD§[§§](#jdi12235-note-0001){ref-type="fn"}     FBG (H), ISI (L), [¶¶](#jdi12235-note-0001){ref-type="fn"}                                                        NA (D)
  Zhang *et al*.[94](#jdi12235-bib-0094){ref-type="ref"}         1 × 25                                        8W, 60 F^L^, %                                                                          180--200 g            SD                                              FPG = 21 (H), FPI = 190 (H), FTG = 2.7 (H), PTC = 2.1 (H)                                                         Early (DS)
  Islam *et al*.[95](#jdi12235-bib-0095){ref-type="ref"}         1 × 40                                        2W, 47C^S,\ ST^, 20P^CA^, 20F^L^, 10O                                                   5 weeks, 120--140 g   SD                                              FBG = 181.7 ± 60.1 (mg/dL), FBI = 61.8 ± 27.3 (pmol/L), HbA1C% = 7.8[¶¶](#jdi12235-note-0001){ref-type="fn"}      NA (D)
  Zhang *et al*.[56](#jdi12235-bib-0056){ref-type="ref"}         2 × 30                                        4W, 48C, 20P, 22F                                                                       200--250 g            W                                               FBG = 14 (H), FI = 64 (S), TG = 1.7 (H), TC = 3.0 (H)                                                             Late (DS)
  Gao *et al*. 2007[96](#jdi12235-bib-0096){ref-type="ref"}      1 × 25                                        4W, 30C^S^, 15F^L^                                                                      210--220 g            SD                                              BG = (H), TG = 0.9 (H), C = 2.6 (S)                                                                               NA (DS)
  Sahin *et al*.[61](#jdi12235-bib-0061){ref-type="ref"}         1 × 40                                        2W, 30C^S,\ S^, 20P^CA^, 40F^AF^, 10O                                                   8 weeks, 200--250 g   SD                                              G = 26 (H), I = 161 (L), TG = 4.4 (H), TC = 6.5 (H)                                                               Late ‐ NA
  Danda *et al*.[97](#jdi12235-bib-0097){ref-type="ref"}         1 × 35 i.v.                                   5W, 60F^AF^, %                                                                          175--200 g            SD                                              BG = (H), Hba1c = 6 (H), C = 3.1 (H), TG = 3.3 (H), [¶¶¶](#jdi12235-note-0001){ref-type="fn"}SI = 84.3            NA (T2D)
  Srinivasan *et al*.[55](#jdi12235-bib-0055){ref-type="ref"}    1 × 35                                        2W, 17K, 25P, 58F, %                                                                    160--180 g            SD                                              PGL = 23 (H), PI = 217 (S), PTG = 2.0 (H), PTC = 4.6 (H)                                                          Late (DS)
  Zhou *et al*.[82](#jdi12235-bib-0082){ref-type="ref"}          1 × 40                                        4W, 54C, 13P, 20F^L^, 5O                                                                4 weeks, 83 ± 5 g     SD                                              FBG = 14 (H), FSI = 60 (S), TG = 3.7 (H), C = 2.6 (H)                                                             Late (DS)
  Wu *et al*. 2004[98](#jdi12235-bib-0098){ref-type="ref"}       1 × 30 i.v.                                   2W, 41K, 18P, 41F, %                                                                    8 weeks               SD                                              FBG = 7 (H), I = 77 (S)                                                                                           Late (DS)
  Zhang *et al*.[81](#jdi12235-bib-0081){ref-type="ref"}         1 × 15 i.v.                                   8W, 50C, 13P, 30F                                                                       8 weeks               SD                                              FBG = 17 (H), FSI = 120 (S), TG = 3.8 (H), C = 2.4 (H)                                                            Late (DS)
  Yang *et al*. 2003[71](#jdi12235-bib-0071){ref-type="ref"}     1 × 15 i.v.                                   8W, 40C, 13P, 40F, 7O                                                                   8 weeks               SD                                              FBG = (H), TG = (H), C = (H)                                                                                      NA (DS)
  Reed *et al*.[54](#jdi12235-bib-0054){ref-type="ref"}          1 × 50                                        2W, 41C, 18P, 40F                                                                       7 weeks, 200 g        SD                                              BG = 21 (H), I = 186 (H), TG = 7.5 (H)                                                                            Early (DS)

\*STZ treatment: Number of doses × dose (mg/kg) of Streptozotocin. The route of administration was intraperitoneally unless otherwise indicated; intraveneously (i.v.). †Diet (duration): Duration of diet regimen in weeks (W) before STZ treatment. ‡Diet (nutritional content): dietary Carbohydrate percentage (C): Starch (ST), Sucrose (s); dietary Fat percentage (F): Animal Fat (AF), Lard (L), Coconut Oil (CN), Vegetable Oil (VO): dietary Protein percentage (P): Casein (CA), Milk Powder (MP), Soy Bean (SB); dietary Cholesterol percentage (CO); dietary percentage of Other components than C, F, P and CO (O); Normal diet (ND); %kca is specified with '%'. §Strain of male rats: Sprague Dawly (SD); Wistar (W); Albino (A); \*\*Female. §§Metabolic measures: The metabolic measure was either Higher (H) or Lower (L) in the HFD/STZ rat than in lean controls, or the same (S). All data have been converted to SI units. The mM Unit was used for: Glucose (G), Blood Glucose (BG), Plasma Glucose (PG), Fasting Glucose (FG), Fasting Blood Glucose (FBG), Triglycerides (TG), Fasting Triglycerides (FTG), Total Cholesterol (TC), Plasma Triglycerides (PTG), Plasma Total Cholesterol (PTC), High‐Density Lipoprotein (HDL), Low‐Density Lipoprotein (LDL); The pM Unit was used for: Insulin (I), Plasma Insulin (PI), Fasting Blood Insulin (FBI), Fasting Serum Insulin (FSI); The mg/mL Unit was used for serum adiponectin (APQ); Homeostasis Model of Assessment of β‐cell function (HOMA‐B); Homeostasis Model of Assessment of Insulin Resistance (HOMA‐IR); Insulin Sensitivity Index (ISI), Insulin Resistance Index (IRI); ¶¶Statistics against controls were not provided, ¶¶¶No lean controls were included. \*\*Stage of type 2 diabetes (T2D): Whether the animal model mimics the Early versus the Late stage of type 2 diabetes was based on the levels of insulin and glucose provided in the study. The model was concluded be mimic the early stage if glucose and insulin levels were higher than in controls, whereas the model was concluded to mimic the late stage if insulin levels were lower than or the same as in controls. ††Nomenclature for the HFD/STZ rat model: Type 2 diabetes (T2D); diabetes (D); according to the Diet and STZ treatments (DS); lack of meatabolic parameters to classify the model or lack of nomenclature (NA).
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In our experience, 5 weeks of high‐fat/high‐sucrose (HF/HS) feeding induced a higher body fat percentage and impaired glucose tolerance along with hyperinsulinemia (S. Skovsø, unpublished data). In contrast, induction of insulin resistance, by even shorter high‐fat diet regimens, has been reported.[54](#jdi12235-bib-0054 jdi12235-bib-0055 jdi12235-bib-0056){ref-type="ref"} Furthermore, short periods of HFD feeding have been reported to simulate insulin resistance in lean patients, which is different from 'true' obese state that might take a much longer time to replicate in rats[57](#jdi12235-bib-0057){ref-type="ref"}. Thus, one should carefully consider the length and nutritional composition of the diet regimen, depending on what state one wants to mimic. Short diet regimens (2 weeks) tend to just induce insulin resistance and/or glucose intolerance, whereas relatively longer diet periods (5 weeks) can also induce a higher body fat percentage. Hence, this relatively short diet feeding seems to mimic the human situation of prediabetes, including obesity and hyperinsulinemia, more appropriately than the short diet regimens. Even longer feeding timeframes (\> 3 months) are preferred when aiming for 'true' obesity including significant bodyweight increases.

HFD/STZ rats are often reported to be dyslipidemic, similar to the metabolic profile of type 2 diabetes in humans. Whether this is a direct consequence of the diet regimen alone is rarely reported in the literature. Data comprising the presence of hyperinsulinemia, obesity and impaired glucose tolerance, all representing the prediabetes state, are also rarely reported in the literature at the time‐point before initiation of STZ treatment. Such data, before establishment of severe hyperglycemia with STZ, would be required to underscore similarities with the progression of human type 2 diabetes, with respect to the order of the main pathological events. In unpublished studies, we have found that it is possible to maintain normal fasting glucose levels while significantly increasing the levels of total body fat (magnetic resonance imaging scanning), the liver fat (computed tomography scanning), plasma C‐peptide and triglyceride, as a consequence of a 5‐week HFD diet regimen consisting of 4 kcal% fat (lard), 35% carbohydrate (corn starch, sucrose, and maltodextrin) and 20% protein (casein), before initiation of STZ treatment (S. Skovsø, unpublished data). Furthermore, similar to the findings of other groups[54](#jdi12235-bib-0054 jdi12235-bib-0055){ref-type="ref"}, we have observed glucose intolerance in HFD‐fed rats. After STZ treatment of HFD‐fed rats, we and others have observed profound hyperglycemia, low levels of circulating adiponectin[60](#jdi12235-bib-0060){ref-type="ref"}, and high levels of plasma alanine aminotransferase[61](#jdi12235-bib-0061){ref-type="ref"} (S. Skovsø, unpublished data). In summary, the diet regimen is one of the most important factors to consider in the HFD/STZ rat model.

Does STZ Treatment Make the Model a Type 1 or a Type 2 Diabetes Animal Model? {#jdi12235-sec-0007}
-----------------------------------------------------------------------------

The final event involved in the development of type 2 diabetes is β‐cell failure/death[5](#jdi12235-bib-0005 jdi12235-bib-0049){ref-type="ref"}. This is also the case in type 1 diabetes[62](#jdi12235-bib-0062){ref-type="ref"}. Hence, the β‐cell toxin, STZ, has been used in both type 1 and type 2 diabetes animal models[55](#jdi12235-bib-0055 jdi12235-bib-0056){ref-type="ref"}. The STZ dose will greatly affect the β‐cell mass remaining in the rats. Likewise, variation in the amount of β‐cell mass left in both type 1 and type 2 diabetes exists in humans[6](#jdi12235-bib-0006 jdi12235-bib-0063){ref-type="ref"}. Despite the lack of non‐invasive measurement techniques, it has been suggested that 60--80% of the functional β‐cell mass is lost by the time of diagnosis of type 1 diabetes[63](#jdi12235-bib-0063){ref-type="ref"}. In contrast, only a 24% reduction has been observed in patients with a \< 5 years' history of type 2 diabetes compared to controls[64](#jdi12235-bib-0064){ref-type="ref"}. However, another study has reported a 54% reduction in β‐cell mass 15 years after diagnosis of type 2 diabetes[64](#jdi12235-bib-0064){ref-type="ref"}. Collectively, these data suggest a similarity in β‐cell mass, when comparing early type 1 and late stage type 2 diabetes.

This observation suggests that the HFD/STZ rat model could mimic the case of early type 1 diabetes coexisting with obesity. However, obesity is more often seen in patients after their type 1 diabetes diagnosis, whereas obesity is often seen decades before the diagnosis of type 2 diabetes. Thus, the order of the pathological events, obesity followed by β‐cell failure, seen in HFD/STZ rats favors a mimicking of type 2 diabetes rather than type 1 diabetes, despite the observed similarity between early type 1 diabetes and late type 2 diabetes. Furthermore, the loss of β‐cell mass in the pathogenesis of type 1 diabetes occurs mainly as a result of an autoimmune reaction[63](#jdi12235-bib-0063){ref-type="ref"}, which is not the case in HFD/STZ rats. In contrast, the events leading to β‐cell compensatory mechanisms and subsequent β‐cell failure in type 2 diabetes involve lipotoxicity and/or glucolipotoxicity, insulin resistance, hyperinsulinemia, and stress, with a modest contribution from low‐level inflammation[9](#jdi12235-bib-0009){ref-type="ref"}. In other words, the different causalities that induce β‐cell death in type 1 and type 2 diabetes cannot be mimicked to perfection by STZ treatment in animal models.

Despite the lack of the autoimmune component, HFD‐fed rats treated with just a single high dose of STZ show clear features of type 1 diabetes, such as hyperglycemia, insulin deficiency, drastic weight loss and resistance towards insulin‐sensitizing therapeutics[55](#jdi12235-bib-0055 jdi12235-bib-0056 jdi12235-bib-0065){ref-type="ref"}. Furthermore, STZ treatment of both lean‐STZ (a frequently used model of type 1 diabetes[55](#jdi12235-bib-0055 jdi12235-bib-0056 jdi12235-bib-0066){ref-type="ref"}; 3 × 30 mg STZ/kg bodyweight, once daily for 3 days) and HFD/STZ rats (3 × 20 mg STZ/kg bodyweight, once daily for 3 days) are often associated with an initial weight loss (S. Skovsø, unpublished data), whereas both models respond with a weight gain after 3 weeks of insulin therapy (S. Skovsø, unpublished data). An insulin‐induced weight gain is commonly seen during insulin therapy in type 1 and type 2 diabetes patients.[67](#jdi12235-bib-0067 jdi12235-bib-0068){ref-type="ref"} In contrast to type 1 diabetes, a clear and sudden weight loss is not observed on diagnosis of type 2 diabetes. However, patients with undiagnosed and/or non‐insulin‐treated overt type 2 diabetes would inevitably also face a significant weight loss with time. Thus, the STZ‐induced weight loss and gain in weight on insulin therapy, which we have observed in the HFD/STZ rat model, does not make the model a better model of type 1 diabetes than of type 2 diabetes, as they are phenomena potentially occurring in both diseases.

Confusion has been added into the literature by the fact that some high‐fat fed rat models, treated with the same high dose of STZ used when modeling type 1 diabetes, have also been referred to as models of type 2 diabetes in other studies[54](#jdi12235-bib-0054 jdi12235-bib-0069){ref-type="ref"}. However, when the STZ dose is changed from a single high dose to a single low dose or multiple lower doses of STZ, researchers tend to agree on the HFD/STZ rat as a suitable model of type 2 diabetes[55](#jdi12235-bib-0055 jdi12235-bib-0056 jdi12235-bib-0059 jdi12235-bib-0061){ref-type="ref"} (Table [1](#jdi12235-tbl-0001){ref-type="table-wrap"}). Thus, the dose of STZ in itself obviously has a significant impact on the phenotype of HFD‐fed rats. STZ treatment induces robust (but not absolute) β‐cell ablation in a manner that depends on the dose, the number of doses, the time interval between doses, the route of administration, the fed/fasted state upon STZ administration, and the rat strain/vendor. There are great variations in the STZ treatments, which affect the level of β‐cell depletion. Variations among these parameters also exist in studies working with the HFD/STZ rat model (Table [1](#jdi12235-tbl-0001){ref-type="table-wrap"}).

The same STZ treatment has been applied to rats on different diet regimens, and thus rats with potentially different body compositions might also result in different phenotypes. Data supporting this concept are found in studies comparing lean STZ rats with HFD/STZ rats treated with the same amount of STZ. These rats do not show the same phenotype in respect to blood glucose levels.[54](#jdi12235-bib-0054){ref-type="ref"} This might be related to the fact that STZ has been shown not to interact with lipids[70](#jdi12235-bib-0070){ref-type="ref"}. Another possibility could be varying levels of glucose transporter 2, required for STZ entry into β‐cells, in the two models. Another caveat to remember when treating HFD fed animals with STZ is that diabetes induced by STZ treatment can lead to increased insulin sensitivity when compared with controls[71](#jdi12235-bib-0071){ref-type="ref"}. In contrast, type 2 diabetes in humans is characterized by insulin resistance[9](#jdi12235-bib-0009){ref-type="ref"}. Finally, when discussing the affect of STZ treatment with respect to the HFD/STZ model, it should be stressed that the STZ treatment leads to a transition from an insulin‐resistant state to a state of type 2 diabetes in a very fast and unnatural way. This means that the time aspect of the disease progression/transition is not mimicked ideally in this animal model. In summary, the design of the STZ treatment superimposed on the choice of the diet regimen will greatly affect the phenotype of the HFD/STZ rat model. No absolute agreement of the STZ treatment approach exists in the literature when it comes to modeling of type 2 diabetes in the HFD/STZ rat model, though some tendencies appear (Table [1](#jdi12235-tbl-0001){ref-type="table-wrap"}).

Impact of Age in HFD/STZ Models When Deciding on the Type of Diabetes Model {#jdi12235-sec-0008}
---------------------------------------------------------------------------

Type 2 diabetes remains mainly a disease of older humans[72](#jdi12235-bib-0072){ref-type="ref"}. Thus, another important factor in modeling the HFD/STZ diabetes rat model is age. The vast majority of HFD/STZ rats used in the literature are young rats (\< 6 months; Table [1](#jdi12235-tbl-0001){ref-type="table-wrap"}). The young age of the rats make them a potential disease model for diabetes present in young human individuals. It is arguable that young HFD/STZ rats with a massive loss of functional β‐cell mass mimic type 1 diabetes in children who are obese, but without the autoimmune component hallmarking of type 1 diabetes[73](#jdi12235-bib-0073){ref-type="ref"}. In contrast, young HFD/STZ rats bearing a somewhat lower depletion of β‐cell mass mimic obese children with type 2 diabetes. Notably, the prevalence of type 2 diabetes in young children and adolescents has increased with a rapid pace[74](#jdi12235-bib-0074){ref-type="ref"}. Importantly, the pathogenesis of type 2 diabetes in young vs older individuals has indirectly been shown to be different from one another[75](#jdi12235-bib-0075){ref-type="ref"}; where young type 2 diabetes patients have a tendency to be insulin deficient, the elderly have a tendency to be more insulin resistant. This fits with knowledge from genome‐wide association studies pointing to genetic defects in β‐cell function, and the general concept that earlier diagnosis would be associated with a greater genetic contribution. This point also favors the young HFD/STZ rats to be a model for type 2 diabetes in young individuals, as STZ treatment brings about insulin secretion deficiency rather than insulin resistance. It is important to mention that young rodents, like young people, have the capacity to increase β‐cell mass[76](#jdi12235-bib-0076){ref-type="ref"}. Older rodents (aged \>1 year) and older people (aged \>30 years) do not seem to have this capacity[76](#jdi12235-bib-0076){ref-type="ref"}. This partly explains why it can be so challenging to administer the correct dose of STZ to induce the state of diabetes intended for the investigation. Collectively, these observations stress the importance of choosing the age of the rats when modeling type 2 diabetes in the HFD/STZ rat model.

Early vs Late Stage Type 2 Diabetes: STZ Treatment and β‐Cell Functionality in High‐Fat Fed Rats {#jdi12235-sec-0009}
------------------------------------------------------------------------------------------------

So far, different ways of modeling type 2 diabetes, in the HFD/STZ rat model, have been discussed in the present review. However, another important question centers around whether the HFD/STZ rat mimics an *early* or *late* stage of type 2 diabetes. This is an important issue because of the principal metabolic differences present in subjects having had type 2 diabetes for either a shorter or longer period, including the level of remnant functional β‐cell mass[6](#jdi12235-bib-0006 jdi12235-bib-0064){ref-type="ref"}. This emphasizes the importance of characterizing the amount of, and more importantly, the function of the remaining β‐cells and the level of insulin resistance when working with the HFD/STZ rats. This is not reported consistently in preclinical studies. In contrast, clinical studies have stressed the importance of dividing type 2 diabetes patients into subgroups, based on their disease duration and severity, as well as on the length, intensity and choice of[77](#jdi12235-bib-0077){ref-type="ref"}. Feyter *et al*.[77](#jdi12235-bib-0077){ref-type="ref"} investigated muscle mitochondrial dysfunction and divided their patients into four different subgroups: (i) long‐standing insulin‐treated type 2 diabetes patients; (ii) patients with impaired fasting glucose; (iii) impaired glucose tolerance and/or recently diagnosed type 2 diabetes; and (iv) healthy, normoglycemic controls. Such clinical studies raise the awareness of the importance to also divide the type 2 diabetes animal models in respect to the state of the disease. It can be argued as to whether classifications should be the same in animal models. It should be possible to make a 'rough' division of type 2 diabetes patients based on the duration of the disease alone, dividing them into an early phase and late phase cohort. Both early and late stage type 2 diabetes patients have hyperglycemia, but individuals in the early phase might still have relatively high levels of insulin. In contrast, late phase patients have similar or lower levels of insulin compared with weight‐matched controls.

Likewise, one can find examples of HFD/STZ rat models with elevated blood glucose levels coexisting with either higher, lower or the same levels of insulin when compared with lean controls (Table [1](#jdi12235-tbl-0001){ref-type="table-wrap"}). Despite the demonstration of these data in some studies, the categorization (early vs late) is rarely reported in studies using the HFD/STZ rat model. Such a grouping is especially important when testing therapeutics for type 2 diabetes, aiming towards either the early or the late stage of type 2 diabetes.

In this review, the HFD/STZ rat models used in the various studies have been classified into models representing either the early or the late stage of type 2 diabetes (Table [1](#jdi12235-tbl-0001){ref-type="table-wrap"}). The classification is based on the levels of glucose and insulin, and has thus only been possible for the studies providing these parameters for both the HFD/STZ rats and their HFD controls. Only few studies have more thoroughly investigated the stage of type 2 diabetes by examining the pathological state of the pancreas through investigation of oxidative stress markers, anti‐oxidative markers, islets area, insulin positive cells and/or cell death in the endocrine pancreas[61](#jdi12235-bib-0061 jdi12235-bib-0069 jdi12235-bib-0078 jdi12235-bib-0079 jdi12235-bib-0080 jdi12235-bib-0081 jdi12235-bib-0082){ref-type="ref"}. Naturally, without this information, it is not possible to fully understand whether the HFD/STZ rat model corresponds to an early or a late stage of type 2 diabetes. Researchers working with the HFD/STZ rat animal model, as well as researchers working with other type 2 diabetes models, are encouraged to provide data (at least glucose and insulin/c‐peptide levels), which can be used for identifying the stage of type 2 diabetes mimicked in the specific HFD/STZ rat model.

Conclusions {#jdi12235-sec-0010}
===========

In the present review, the metabolic profile of the different stages of type 2 diabetes progression in both humans and HFD/STZ rats are reviewed, and some similarities and differences are highlighted. The evolution of this model is reviewed in the context of efforts to more accurately model human type 2 diabetes. The specific variations in the dietary regimen, STZ treatment and age used in HFD/STZ rat models are discussed thoroughly. Finally, the importance of considering whether a specific HFD/STZ rat model mimics an early or late stage of human type 2 diabetes is considered. It is clear that more basic characterization needs to be carried out on this model, and this review has provided some guidance on how to proceed. Finally and most importantly, it is the opinion of this author that, despite its limitations and the wide variety of both the high‐fat fed regimen and the STZ treatment, the HFD/STZ is a reasonable animal model of type 2 diabetes mainly representing the later stage of the disease depending on the amount of residual β‐cell mass.

The author gratefully thanks Jim Johnson, University of British Columbia, for helpful and critical comments during the writing of this manuscript. Furthermore, Xenia Asbæk Wolf and Bidda Rolin from the department of Translational Pharmacology, Novo Nordisk, Måløv, Denmark, are thanked for assistance and encouragement in the writing of this review. The author declares that there is no conflict of interest associated with this work.
